Shenouda Maged 4
4 · RELMADA THERAPEUTICS, INC. · Filed May 30, 2023
Insider Transaction Report
Form 4
Shenouda Maged
Chief Financial Officer
Transactions
- Award
Stock Option (right to buy)
2023-05-25+317,643→ 512,560 totalExercise: $3.37From: 2023-03-16Exp: 2032-12-16→ Common Stock (317,643 underlying)
Footnotes (2)
- [F1]The option grant was approved by the Board of Directors of the Company on December 16, 2022, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan, as amended (the "Plan"), increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2023, at the 2023 Annual Meeting of the Company's shareholders.
- [F2]62,560 of the options immediately vested; 450,000 options vest in 16 equal quarterly installments commencing on March 16, 2023.